1. Home
  2. STEW vs IVA Comparison

STEW vs IVA Comparison

Compare STEW & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SRH Total Return Fund Inc.

STEW

SRH Total Return Fund Inc.

HOLD

Current Price

$18.03

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

HOLD

Current Price

$6.57

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STEW
IVA
Founded
N/A
2011
Country
United States
France
Employees
N/A
84
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
STEW
IVA
Price
$18.03
$6.57
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$16.20
AVG Volume (30 Days)
94.8K
419.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.00
$2.70
52 Week High
$18.67
$7.98

Technical Indicators

Market Signals
Indicator
STEW
IVA
Relative Strength Index (RSI) 49.58 57.21
Support Level $17.64 $4.34
Resistance Level $18.34 $7.29
Average True Range (ATR) 0.23 0.31
MACD -0.01 0.01
Stochastic Oscillator 37.33 61.71

Price Performance

Historical Comparison
STEW
IVA

About STEW SRH Total Return Fund Inc.

SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: